Department of Ophthalmology, Otolaryngology & Dermatology, Dongshin University College of Korean Medicine, Naju-si, Korea (the Republic of).
Department of Ophthalmology, Otolaryngology & Dermatology, Dongshin University College of Korean Medicine, Naju-si, Korea (the Republic of)
BMJ Open. 2024 Jan 3;14(1):e077913. doi: 10.1136/bmjopen-2023-077913.
The prevalence of dry eye disease (DED) has been consistently increasing yearly. However, the radical therapy has not yet been established. This study is to confirm the superiority of acupuncture over artificial tear drops (ATDs) in patients with DED.
This study is a single-centre, investigator-initiated, assessor-blinded, parallel randomised controlled trial. 30 participants will be enrolled. Over a period of 4 weeks, the experimental group would receive two kinds of acupuncture three times a week. First, body acupuncture would be performed on bilateral BL2, GB14, TE23, EX-HN5 and ST1 for 15 min. Thereafter, intradermal acupuncture would be performed on the same acupoints for 4 hours. On the other hand, the control group would apply the provided ATD at least four times a day. As a rescue medication for severe DED symptoms, both groups can additionally apply ATD. The frequency of ATD use would be recorded during the trial. The primary outcomes are the Ocular Surface Disease Index and tear film break-up time. The secondary outcomes are subjective symptom Visual Analogue Scale, quality of life, Schirmer I test, tear lactoferrin level, treatment satisfaction and safety. The outcomes would be mostly assessed at visits 1, 13 and 14.
This study was approved by the institutional review board of Naju Dongshin University Korean Medicine Hospital (Approval No. NJ-IRB-23-5). The obtained results will be disseminated through publication in a peer-reviewed journal.
KCT0008563.
干眼症 (DED) 的患病率一直在逐年持续上升。然而,尚未确立根治疗法。本研究旨在确认针灸在 DED 患者中的疗效优于人工泪液滴注 (ATD)。
这是一项单中心、研究者发起、评估者设盲、平行随机对照试验。将纳入 30 名参与者。在 4 周的时间内,实验组每周接受 3 次两种类型的针灸治疗。首先,对双侧 BL2、GB14、TE23、EX-HN5 和 ST1 进行体针治疗 15 分钟。然后,在相同的穴位上进行皮内针治疗 4 小时。另一方面,对照组每天至少滴注 4 次提供的 ATD。对于严重 DED 症状,两组均可额外使用 ATD。试验期间将记录 ATD 的使用频率。主要结局指标是眼表疾病指数和泪膜破裂时间。次要结局指标是主观症状视觉模拟量表、生活质量、泪液分泌试验、泪乳铁蛋白水平、治疗满意度和安全性。结果主要在第 1、13 和 14 次就诊时进行评估。
本研究已获得牙山市东南大学韩医医院机构审查委员会的批准(批准号:NJ-IRB-23-5)。研究结果将通过发表在同行评议的期刊上进行传播。
KCT0008563。